In 1978, researchers first described residual adenosine deaminase activity in the tissue of patients with severe combined immunodeficiency due to deleterious mutations in ADA, encoding for human adenosine deaminase (hereafter referred to as ADA1).1 This evidence concerns the gene ADA and Immunodeficiency.